You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

Filtered By:
18 Items
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
Exceptional Access Program
    Treatment of non-small cell lung cancer according to clinical criteria
... Show more tags
Drugs Used:
alectinib
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2019
Cancer Type: Gastrointestinal, Neuroendocrine (GI)     
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
... Show more tags
Drugs Used:
capecitabine,
temozolomide (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
... Show more tags
Drugs Used:
daSATinib
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    daSAtinib - PH+ ALL, with specific criteria
... Show more tags
Drugs Used:
daSATinib
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
... Show more tags
Drugs Used:
ixazomib (Unfunded),
lenalidomide (Unfunded),
dexamethasone
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Sarcoma, Ewing's     
Intent: Palliative
Drugs Used:
temozolomide (Unfunded),
irinotecan
... Show more tags
Quick Link(s):
Regimen Monograph
Oct 2017
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Drugs Used:
ixazomib (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Gastrointestinal, Neuroendocrine (GI), Lung, Neuroendocrine (Lung)     
Intent: Palliative
Funding:
ODB - General Benefit
    octreotide
... Show more tags
Drugs Used:
octreotide
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2019
Cancer Type: Gastrointestinal, Hepatobiliary / Liver / Bile Duct     
Intent: Palliative
Funding:
Exceptional Access Program
    SORAfenib - Advanced hepatocellular carcinoma, with specific criteria
... Show more tags
Drugs Used:
SORAfenib
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2019
Cancer Type: Genitourinary, Renal cell / Kidney     
Intent: Palliative
Funding:
Exceptional Access Program
    SORAfenib - Metastatic renal cell carcinoma of clear cell histology as second-line treatment, with specific criteria
... Show more tags
Drugs Used:
SORAfenib
... Show more tags
Quick Link(s):
Regimen Monograph
Aug 2019
Cancer Type: Endocrine, Thyroid     
Intent: Palliative
Drugs Used:
SORAfenib (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2019
Cancer Type: Hematologic, Leukemia - Acute Myeloid (AML)     
Intent: Curative
Drugs Used:
SORAfenib (Unfunded)
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2019